Eli Lilly appoints Lucas Montarce as CFO - Breaking The News
Download our appPlay StoreApp Store

Eli Lilly appoints Lucas Montarce as CFO

EPA-EFE/RONALD WITTEK

Eli Lilly and Company announced in a press release on Monday that it is appointing Lucas Montarce as its new executive vice president and chief financial officer, effective immediately.

"I am committed to building on our strong financial foundation and helping drive continued success as we expand our global footprint and deliver long-term value to our stakeholders," Montarce stated and added that he was "honored" to take up this new position at the pharmaceutical company. The incoming CFO joined Eli Lilly back in 2001, and his previous position at the company was as the president and general manager of Eli Lilly's Spain, Portugal, and Greece hubs.

The departure of the previous CFO, Anat Ashkenazi, was announced back in June. Ashkenazi left Eli Lilly to join Google and Alphabet as its new senior vice president and CFO.

Related Stocks
Eli Lilly and
Related News
China's VP He meets with Apple's Cook
Chinese Vice Premier and Central Financial and Economic Affairs Commission Office Director He Lifeng met with the heads of various major companies from North America to discuss the trade relations between Beijing and the United States, the Asian country's Commerce Ministry (MOFCOM) said in a statement issued on Monday.He met with the leaders of Pfizer Inc., Brookfield Corporation, Mastercard Inc., Cargill Incorporated, Corning Inc., and Apple Inc., with the...
Eli Lilly to debut weight loss drug in China, India
Eli Lilly & Co. is preparing to introduce its widely sought-after diabetes and weight-loss medication Mounjaro in key markets such as China, India, Brazil, and Mexico this year, CEO Lucas Montarce revealed on Monday."The size is significant. We're talking about 900 million patients that could benefit from Mounjaro," Montarce stated at the Leerink Partners Global Healthcare Conference.Demand for obesity and diabetes treatments from Lilly and its Danish...
Eli Lilly warns US trade restrictions on China could impact business
Eli Lilly & Co. warned Wednesday that escalating US-China trade tensions could significantly affect its operations and could lead to further disruptions in supply chains and manufacturing. This was said in its annual report to the US Securities and Exchange Commission.The pharmaceutical giant, which has manufacturing sites in the US, Ireland, Germany, and Puerto Rico, relies on global supply chains to meet product demand. While expanding operations in...
Eli Lilly's Q4 revenue jumps 45% to $13.5B
Eli Lilly and Co. reported on Thursday that its revenue for the fourth quarter of 2024 surged 45% year-over-year to $13.5 billion, exceeding expectations. Net income came to $4.4 billion, soaring 101% annually, with earnings per share (EPS) jumping 102% to $4.88. In the full-year 2024, Eli Lilly posted a 32% increase in revenue to $45 billion, and a 102% rise in net income to $10.5 billion and EPS to $5.20. The company said it expects 2025 revenue to be...

Please observe our Terms of Use. The price information is time delayed to varying extents, but as a rule by 15 minutes or more, according to the regulations of the selected stock exchange and/or licensors and the type of securities.

© 2025 TeleTrader Software GmbH. All rights reserved

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.